Mesoblast Q1 FY2027: US$28M Ryoncil Revenue, US$98.5M Cash, 46 Quarters of Runway
MESO sits 33% above its 52-week low of $11.89.
Summary
Mesoblast's Q1 FY2027 Appendix 4C shows US$28M of Ryoncil revenue (up 44%), operating cash burn down to US$2.1M, and US$98.5M of cash — enough for 46.3 quarters at that rate. The FDA also confirmed the rexlemestrocel-L BLA may proceed for LVAD-related GI bleeding.
Key Events · Earnings and Guidance · MESO
-
Ryoncil Revenue Up 44% to US$28M
First-quarter FY2027 Ryoncil net revenue was US$28M versus the prior year period, with September the strongest month for new patient starts after the usual July-August summer lull.
-
Cash Burn Falls to US$2.1M
Net operating cash spend was US$2.1M for the quarter, an 86% improvement on US$14.9M a year earlier, against US$35.4M of customer receipts.
-
US$98.5M Cash, 46 Quarters of Runway
Cash and equivalents stood at US$98.5M at September 30, 2026; the Appendix 4C reports 46.3 estimated quarters of funding available at the current burn rate.
-
FDA Clears Path for Rexlemestrocel-L BLA
The FDA confirmed the BLA may proceed under RMAT and Orphan Drug designations for end-stage heart failure patients on an LVAD with life-threatening major GI bleeding; formal minutes are expected shortly.
Analysis · MESO · Life Sciences
The formal Appendix 4C puts hard numbers on the quarter the company pre-announced on October 16. Ryoncil revenue of US$28M is up 44% year over year, and net operating cash burn collapsed to US$2.1M from US$14.9M — the company is now close to funding itself from product sales. With US$98.5M of cash and a fully drawn US$125M facility, the filing reports 46.3 quarters of funding available, which removes near-term financing risk that has hung over this story. The other piece that matters is regulatory: the FDA confirmed the rexlemestrocel-L BLA may proceed for LVAD patients with life-threatening GI bleeding, a second potential product on top of Ryoncil. The 350-patient CLBP Phase 3 has finished treating all patients, with the 12-month durability readout due next year.
How filings like this one have moved
In the 30 days to Oct 29, 2026, 30.9% of the 1649 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.02%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MESO was trading at $15.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $11.89 to $21.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.